Lilly partner Aktis surges on trading debut
Source: SeekingAlpha
2026-01-09 12:28:51 ET
More on Aktis Oncology, Inc., Eli Lilly
- Eli Lilly's 2026 Resolution: Volume Is The New Price
- Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies
- Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum
- Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery
- Aktis Oncology prices IPO at $18 per share
Read the full article on Seeking Alpha
For further details see:
Lilly partner Aktis surges on trading debut
Akoustis Technologies Inc.
NASDAQ: AKTS
AKTS Trading
0.19% G/L:
$18.925 Last:
147,135 Volume:
$18.01 Open:
AKTS Latest News
February 24, 2026 08:00:00 am
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
AKTS Stock Data
$997,718,904
32,721,380
0.16%
6
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
